Evaluation of the dislocation and long-term sonographic detectability of a hydrogel-based breast biopsy site marker

Breast Cancer ◽  
2018 ◽  
Vol 25 (5) ◽  
pp. 575-582 ◽  
Author(s):  
Naomi Sakamoto ◽  
Eisuke Fukuma ◽  
Yuko Tsunoda ◽  
Ko Teraoka ◽  
Yoshitomo Koshida
Radiology ◽  
2001 ◽  
Vol 221 (2) ◽  
pp. 504-507 ◽  
Author(s):  
Elizabeth S. Burnside ◽  
Rita E. Sohlich ◽  
Edward A. Sickles

Author(s):  
J. Lambert ◽  
T. Steelandt ◽  
S. H. Heywang-Köbrunner ◽  
K. Gieraerts ◽  
I. Van Den Berghe ◽  
...  

2011 ◽  
Vol 1 (3) ◽  
pp. 222-226 ◽  
Author(s):  
Sumaporn Makkun ◽  
Jenjeera Prueksadee ◽  
Jatuporn Chayakulkheeree ◽  
Darunee Boonjunwetwat

Author(s):  
Sharon Smith ◽  
Clayton R. Taylor ◽  
Estella Kanevsky ◽  
Stephen P. Povoski ◽  
Jeffrey R. Hawley

Breast Care ◽  
2020 ◽  
Vol 15 (6) ◽  
pp. 628-634
Author(s):  
Clara Park ◽  
Frauke Chevalier ◽  
Volker Möbus ◽  
Petra Hoedl ◽  
Kerstin Engelmann ◽  
...  

<b><i>Purpose:</i></b> The aim of this study was to evaluate the feasibility and the accuracy of a secondary, metachronous ultrasound (US)-guided marking of the stereotactic vacuum-assisted breast biopsy (ST-VABB) area. <b><i>Materials and Methods:</i></b> The institutional ethics committee approved the study. The retrospective study included 98 patients. In ST-VABB of 45 women, no tissue markers were deployed at the biopsy site, even if no residual calcifications remained. After histology proved the necessity for a subsequent operation, the biopsy site was marked under US guidance using a coil marker. All interventions were technically successful. No complications occurred. Mammography was done to visualize the coil deployment. The distances from the center of the lesion and the biopsy cavity to the coil location were measured in both planes to evaluate the accuracy of the marking procedure. <b><i>Results:</i></b> In 24 of the 46 cases, the whole lesion was biopsied without residual elements. The mean time between ST-VABB and sonographic marking of the lesion was 9.7 days (median 6.5). The biopsy cavity could be detected in 40 (87%) cases and thus marked exactly. The mean time of US-guided marking was 12.5 min. The mean distance between the coil and the target lesion was 0.6 ± 1.5 cm in the craniocaudal (cc) view and 0.5 ± 1.5 cm in the mediolateral (ml) view for all markings. The mean delta value from the distance nipple–original lesion and from the distance nipple–coil was 0.85 ± 1.2 cm (median 0.5) in the cc view and 0.88 ± 1.2 cm (median 0.6) in the ml view for all cases. Clip migration was not observed. <b><i>Conclusion:</i></b> Our study demonstrates the feasibility and the technical success of secondary metachronous coil marking of the biopsy site under US guidance after receipt of histology. This approach seems to be a cost-effective alternative to the standard procedure of the primary coil marking especially in all completely removed lesions. It may offer advantages for allergic patients.


Author(s):  
Maria Piraner ◽  
Kelly D’Amico ◽  
Lawrence L Gilliland ◽  
Mary S Newell ◽  
Michael A Cohen

Abstract Objective To determine the best management option (surgical excision versus imaging surveillance) following the diagnosis of pure radial scars (RSs) and RSs with associated additional high-risk lesions (HRLs) encountered on percutaneous core-needle breast biopsy. Methods An IRB–approved retrospective review of the breast imaging reporting system database was performed to identify all cases of pure RS alone or RS plus an additional HRL (papilloma, atypia, lobular neoplasia) diagnosed on core-needle biopsy, from 2007 to 2016, at four breast centers in our institution. Cases with associated malignancy, discordant radiologic-pathologic results, or those lost to follow-up were excluded. The remaining cases were evaluated to determine results of either subsequent surgical excision or long-term follow-up imaging (minimum of two years). Additional data recorded included clinical presentation, breast density, personal and family history of breast cancer, lesion imaging characteristics, and biopsy method. Results The study cohort included 111 patients with 111 lesions: 56.8% (63/111) with RS alone (pure) and 43.2% (48/111) with RS plus additional HRL(s). Out of the 63 radiologic-pathologic concordant pure RSs, there were no upgrades to malignancy in 51 subsequent surgical excisions or 12 long-term surveillance cases (0/63, 0%). Out of the 48 RSs plus additional HRL(s), there were 2 upgrades to malignancy (2/48, 4.2%). Conclusion Cases of radiologic-pathologic concordant pure RS diagnosed at core-needle biopsy do not require surgical excision. On the other hand, surgical excision should be considered for RS plus additional HRLs diagnosed at core-needle biopsy.


1995 ◽  
Vol 59 (1) ◽  
pp. 18-20 ◽  
Author(s):  
James M. Goff ◽  
Mark Molloy ◽  
Maureen T. Debbas ◽  
Douglas A. Hale ◽  
David P. Jaques

Author(s):  
Stefania Montemezzi ◽  
Giuseppe Cardano ◽  
Silvia Storer ◽  
Nicolò Cardobi ◽  
Carlo Cavedon ◽  
...  

Abstract Objectives This study evaluated the feasibility of DWI for lesion targeting in MRI-guided breast biopsies. Furthermore, it assessed device positioning on DWI during biopsy procedures. Methods A total of 87 biopsy procedures (5/87 bilateral) consecutively performed between March 2019 and June 2020 were retrospectively reviewed: in these procedures, a preliminary DWI sequence (b = 1300 s/mm2) was acquired to assess lesion detectability. We included 64/87 procedures on lesions detectable at DWI; DWI sequences were added to the standard protocol to localize lesion and biopsy device and to assess the site marker correct positioning. Results Mass lesions ranged from 5 to 48 mm, with a mean size of 10.7 mm and a median size of 8 mm. Non-mass lesions ranged from 7 to 90 mm, with a mean size of 33.9 mm and a median size of 31 mm. Positioning of the coaxial system was confirmed on both T1-weighted and DWI sequences. At DWI, the biopsy needle was detectable in 62/64 (96.9%) cases; it was not visible in 2/64 (3.1%) cases. The site marker was always identified using T1-weighted imaging; a final DWI sequence was acquired in 44/64 cases (68.8%). In 42/44 cases (95.5%), the marker was recognizable at DWI. Conclusions DWI can be used as a cost-effective, highly reliable technique for targeting both mass and non-mass lesions, with a minimum size of 5 mm, detectable at pre-procedural DWI. DWI is also a feasible technique to localize the biopsy device and to confirm the deployment of the site marker. Key Points • MRI-guided breast biopsy is performed in referral centers by an expert dedicated staff, based on prior MR imaging; contrast agent administration is usually needed for lesion targeting. • DWI represents a feasible, highly reliable technique for lesion targeting, avoiding contrast agent administration. • DWI allows a precise localization of both biopsy needle device and site marker.


Sign in / Sign up

Export Citation Format

Share Document